REDWOOD CITY, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers ...

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers ...

Panelists discuss how successfully integrating subcutaneous (SubQ) therapies into oncology practice depends on comprehensive education, optimized workflows, transparent patient communication, and ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced that an update on the clinical development plan and pre-clinical data with SubQ-8 were presented today in a scientific symposium at the 27th ...

On Tuesday, Cardiol Therapeutics Inc. CRDL CRDL announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel ...

The most common side effects of IV lecanemab are headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of an ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World ...

Transitioning from IV to Sub-Q Darzalex Faspro significantly improved Kennedy's quality of life, reducing treatment time and enhancing productivity. The FDA approved Darzalex Faspro for high-risk ...

The MarketWatch News Department was not involved in the creation of this content. Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with ...

Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in ...

Novel subcutaneous delivery may offer a more patient-friendly alternative to intravitreal injections, with the potential to significantly reduce treatment burden REDWOOD CITY, Calif., June 30, 2025 ...